Lilly Asian Ventures backs Impact's PARP research again, chipping in for $30M Series C led by Decheng Capital
A Chinese biotech running after the “best-in-class” title in the PARP inhibitor field has gathered $30 million to fuel its still early-stage R&D work …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
